Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Psychopharmacology (Berl). 2014 Apr 30;231(21):4231–4240. doi: 10.1007/s00213-014-3566-6

Table 1.

Demographic Characteristics and Scan Parameters by Diagnostic Group

Parameter Controls (n=21) SPD Participants (n=18) pa
Demographic (Mean ± SD unless otherwise noted)
 Age 40.76 ± 5.80 42.30 ± 7.42 0.473
 Sex (% male) 67% 67% 1.00
 Ethnicity (%) 38% C, 48% AA, 14% H 39% C, 22% AA, 39% H 0.959b
 Smoking status (% yes) 29% 29%c 0.955
 Parental education (years) 14.65 ± 3.22d 13.40 ± 4.07d 0.317
 Participant education (years) 15.20 ± 2.09e 14.33 ± 2.91 0.295
Scan parameters (Mean ± SD)
 Injected dose (mCi) 13.24 ± 3.70 11.01 ± 2.93 0.046
 Injected mass (ug) 4.91 ± 1.08 4.32 ± 1.48 0.166
 Specific activity (Ci/mmol) 921.86 ± 285.72 985.00 ± 553.65 0.650
 Plasma free fraction (fp, %) 0.89 ± 0.26f 0.73 ± 0.15 0.024
 VND (mL/cm3) 2.25 ± 0.48 2.17 ± 0.46 0.614

AA=African American; C=Caucasian; H=Hispanic; SD=standard deviation; SPD=schizotypal personality disorder; VND=nondisplaceable distribution volume (measured in the cerebellum to provide a measure of non-specific radioligand binding).

a

For continuous variables, independent-samples t-test; for dichotomous variables, chi-square tests used.

b

Groups were compared on a dichotomized ethnicity variable (Caucasian v. ethnic minority).

c

Smoking status was missing for 1 SPD participant.

d

Parental education was missing for 3 SPD participants and 1 control.

e

Participant education was missing for 1 control.

f

Plasma free fraction was missing for 1 control.

HHS Vulnerability Disclosure